Why FDA alignment could move Alterity’s ATH434 closer to a pivotal MSA test
Find out how FDA alignment on ATH434 could shape Alterity Therapeutics’ pivotal Phase 3 path in multiple system atrophy.
Find out how FDA alignment on ATH434 could shape Alterity Therapeutics’ pivotal Phase 3 path in multiple system atrophy.